Luke O'Neill
Direktor/Vorstandsmitglied bei POOLBEG PHARMA PLC
Profil
Luke O'Neill is the founder of Inflazome Ltd., a company founded in 2016, where he holds the title of Director & Chief Scientific Officer.
Dr. O'Neill is also the founder of Sitryx Therapeutics Ltd.
Dr. O'Neill's current job(s) include being an Independent Non-Executive Director at Poolbeg Pharma Plc.
He is also a Member of the European Molecular Biology Organization, the Royal Irish Academy, and the Trinity Biomedical Sciences Institute, where he holds the title of Professor.
Dr. O'Neill's former job(s) include being a Director & Chief Scientific Officer at Senda Biosciences, Inc. and a Professor at Trinity College Dublin.
Dr. O'Neill obtained a doctorate degree from the University of London.
Aktive Positionen von Luke O'Neill
| Unternehmen | Position | Beginn |
|---|---|---|
| POOLBEG PHARMA PLC | Direktor/Vorstandsmitglied | - |
| European Molecular Biology Organization | Corporate Officer/Principal | 01.01.2005 |
Inflazome Ltd.
 Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland. | Gründer | 01.01.2016 |
| Trinity Biomedical Sciences Institute | Corporate Officer/Principal | - |
| Royal Irish Academy | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Luke O'Neill
| Unternehmen | Position | Ende |
|---|---|---|
Sitryx Therapeutics Ltd.
 Sitryx Therapeutics Ltd. Medical SpecialtiesHealth Technology Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom. | Gründer | - |
Senda Biosciences, Inc.
 Senda Biosciences, Inc. BiotechnologyHealth Technology Kintai Therapeutics, Inc. engages in discovering and development of precision enteric medicine. It offers discovery platform, enteric biology and analytics, and precision enteric medicines. The company was founded in 2016 and is headquartered in Cambridge, MA. | Technik-/Wissenschafts-/F&E-Leiter | - |
| Trinity College Dublin | Corporate Officer/Principal | - |
Ausbildung von Luke O'Neill
| University of London | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| POOLBEG PHARMA PLC | Health Technology |
| Private Unternehmen | 5 |
|---|---|
| European Molecular Biology Organization | |
| Trinity Biomedical Sciences Institute | |
Inflazome Ltd.
Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland. | Health Technology |
Sitryx Therapeutics Ltd.
Sitryx Therapeutics Ltd. Medical SpecialtiesHealth Technology Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom. | Health Technology |
Senda Biosciences, Inc.
Senda Biosciences, Inc. BiotechnologyHealth Technology Kintai Therapeutics, Inc. engages in discovering and development of precision enteric medicine. It offers discovery platform, enteric biology and analytics, and precision enteric medicines. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |